Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efavaleukin alfa - Amgen

Drug Profile

Efavaleukin alfa - Amgen

Alternative Names: AMG 592; IL-2 mutein Fc fusion protein - Amgen

Latest Information Update: 14 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Antirheumatics; Cytoprotectives; Immunoglobulin Fc fragments; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus; Ulcerative colitis
  • Phase I/II Graft-versus-host disease
  • Phase I Inflammation
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 14 Oct 2023 Pooled pharmacodynamics and adverse event data from preclinical and phase I NCT03451422 studies in ulcerative colitis presented at the 31st United European Gastroenterology Week (UEGW-2023)
  • 28 Aug 2023 No recent reports of development identified for phase-I development in Graft-versus-host-disease(In volunteers) in Australia (SC, Injection)
  • 28 Aug 2023 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in USA (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top